Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bexmarilimab + nivolumab
- Development stage
- Phase 2
- Lead developer
- Faron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bexmarilimab + nivolumab is an investigational combination immunotherapy regimen being evaluated for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC) and melanoma. Bexmarilimab is a humanized IgG4 monoclonal antibody that targets Clever-1 (Common Lymphatic Endothelial and Vascular Endothelial Receptor-1), a scavenger receptor expressed on immunosuppressive M2 macrophages. By blocking Clever-1, bexmarilimab aims to reprogram the tumor microenvironment from an immunosuppressive to an immunostimulatory state. Nivolumab is a programmed death-1 (PD-1) immune checkpoint inhibitor that enhances T-cell activity. The combination is being studied in the Phase I/II BLAZE trial (sponsored by the Institute of Cancer Research) to determine if bexmarilimab can resensitize tumors to PD-1 inhibition in patients who have progressed on prior immunotherapy.
- Other names
- bexmarilimab and nivolumabbexmarilimab plus nivolumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)STAB1 (Common lymphatic endothelial and vascular endothelial receptor 1)
Beyond the preview
Go deeper on bexmarilimab + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bexmarilimab + nivolumab.